Richardson PG et al. Randomized, open label Phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): Phase 2 results. Proc ASH 2011;Abstract 634.

Leleu X et al. High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009-02. Proc ASH 2011;Abstract 812.

Dr Lonial is Vice Chair of Clinical Affairs and Director of Translational Research at the Emory University School of Medicine’s Winship Cancer Institute in Atlanta, Georgia.

Dr Richardson is Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute in Boston, Massachusetts.